Mirum CEO Peetz sells 9,108 shares for taxes

Mirum Pharmaceuticals, Inc.’s chief executive officer and director Christopher Peetz reported a sale of 9,108 shares of common stock on February 2, 2026 at a price of $103.3035 per share.

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc.’s chief executive officer and director Christopher Peetz reported a sale of 9,108 shares of common stock on February 2, 2026 at a price of $103.3035 per share. The filing states these shares were sold to cover tax withholding obligations from vesting restricted stock units.

After this transaction, Peetz beneficially owned 160,294 Mirum common shares directly and 187,500 shares indirectly through The Peetz Family Trust. This reflects a routine, tax-related insider transaction rather than an open-market discretionary sale.

Insider Trade Summary

Net Seller: 9,108 shares

Net Sell 2 txns

Insider Peetz Christopher

Role CHIEF EXECUTIVE OFFICER

Sold 9,108 shs ($941K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,108	$103.3035	$941K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 160,294 shares (Direct); Common Stock — 187,500 shares (Indirect, By The Peetz Family Trust)

Footnotes (1)

1. F1. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

FAQ

What insider transaction did Mirum Pharmaceuticals (MIRM) report for Christopher Peetz?

Mirum Pharmaceuticals reported that CEO and director Christopher Peetz sold 9,108 shares of common stock on February 2, 2026 at $103.3035 per share. The filing explains the sale was solely to cover tax withholding obligations from vesting restricted stock units, not a discretionary share sale.

How many Mirum Pharmaceuticals (MIRM) shares does CEO Christopher Peetz own after the reported sale?

After the transaction, Christopher Peetz beneficially owned 160,294 Mirum common shares directly. He also reported indirect beneficial ownership of 187,500 additional shares held by The Peetz Family Trust, according to the Form 4 filing detailing his February 2, 2026 tax-related stock sale.

Why did Mirum Pharmaceuticals (MIRM) CEO Christopher Peetz sell 9,108 shares?

The filing states the 9,108 Mirum shares were sold to cover tax withholding obligations tied to vesting restricted stock units. This type of sale is typically automatic and tax-driven, rather than a discretionary decision to reduce exposure to the company’s stock position.

Was the Mirum Pharmaceuticals (MIRM) insider sale by Christopher Peetz a direct or indirect transaction?

The 9,108-share sale reported for February 2, 2026 was a direct transaction by Christopher Peetz, classified as directly owned stock. Separately, the filing shows he indirectly holds 187,500 Mirum shares through The Peetz Family Trust as part of his overall beneficial ownership.

What roles does Christopher Peetz hold at Mirum Pharmaceuticals (MIRM) in this Form 4?

In the Form 4, Christopher Peetz is identified as both a director and the chief executive officer of Mirum Pharmaceuticals, Inc. His dual leadership roles mean his equity transactions provide insight into the shareholdings of a key member of the company’s senior management team.

What does the footnote in the Mirum Pharmaceuticals (MIRM) Form 4 disclose about the share sale?

The footnote clarifies that the 9,108 shares were sold specifically to satisfy tax withholding obligations related to vesting restricted stock units. This indicates the transaction was linked to compensation mechanics, rather than a discretionary open-market decision to sell Mirum common stock holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 09:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peetz Christopher

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		9,108	D	$103.3035	160,294	D
Common Stock								187,500	I	By The Peetz Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

	/s/ Judit Ryvkin, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.